Header

UZH-Logo

Maintenance Infos

The MSC marker CD248 (Endosialin) is a negative regulator of bone formation


Naylor, Amy J; Azzam, Eman; Smith, Stuart; Croft, Adam; Poyser, Callum; Duffield, Jeremy S; Huso, David L; Gay, Steffen; Ospelt, Caroline; Cooper, Mark S; Isacke, Clare; Goodyear, Simon; Rogers, Michael J; Buckley, Christopher D (2012). The MSC marker CD248 (Endosialin) is a negative regulator of bone formation. Arthritis and Rheumatism, 64(10):3334-3343.

Abstract

OBJECTIVE: CD248 (TEM1/Endosialin) is found on stromal cells and is highly expressed during malignancy and inflammation. The CD248 knockout (CD248(-/-) ) mouse has reduced inflammatory arthritis. The aim of this study was to investigate the functional effect of genetic deletion of CD248 on bone mass. METHODS: Western blotting, PCR and immunofluorescence were used to investigate CD248 expression. MicroCT and 3-point bending of tibiae from 10 week old wildtype or CD248(-/-) were used to measure bone parameters and mechanical properties. Primary osteoblasts were cultured in media containing 10 mM β-glycerophosphate and 50 μg/ml ascorbic acid to induce mineralisation and treated with PDGF-BB. Mineral apposition rate in vivo was calculated by labelling newly formed bone with calcein. RESULTS: Expression of CD248 was seen in human and mouse osteoblasts but not osteoclasts. CD248(-/-) tibiae had higher bone mass and superior mechanical properties (increased load required to cause fracture) compared to WT. CD248(-/-) primary osteoblasts had increased mineralisation in vitro and produced increased bone over 7 days in vivo and failed to decrease mineralisation or increase proliferation in response to PDGF-BB stimulation due to a defect in PDGF signal transduction. CONCLUSION: There is an unmet clinical need to address RA-associated bone loss. Genetic deletion of CD248 in the mouse results in high bone mass due to increased osteoblast-mediated bone formation, suggesting that targeting CD248 in rheumatoid arthritis may have the effect of increasing bone mass as well as the previously reported effect of reducing inflammation.

Abstract

OBJECTIVE: CD248 (TEM1/Endosialin) is found on stromal cells and is highly expressed during malignancy and inflammation. The CD248 knockout (CD248(-/-) ) mouse has reduced inflammatory arthritis. The aim of this study was to investigate the functional effect of genetic deletion of CD248 on bone mass. METHODS: Western blotting, PCR and immunofluorescence were used to investigate CD248 expression. MicroCT and 3-point bending of tibiae from 10 week old wildtype or CD248(-/-) were used to measure bone parameters and mechanical properties. Primary osteoblasts were cultured in media containing 10 mM β-glycerophosphate and 50 μg/ml ascorbic acid to induce mineralisation and treated with PDGF-BB. Mineral apposition rate in vivo was calculated by labelling newly formed bone with calcein. RESULTS: Expression of CD248 was seen in human and mouse osteoblasts but not osteoclasts. CD248(-/-) tibiae had higher bone mass and superior mechanical properties (increased load required to cause fracture) compared to WT. CD248(-/-) primary osteoblasts had increased mineralisation in vitro and produced increased bone over 7 days in vivo and failed to decrease mineralisation or increase proliferation in response to PDGF-BB stimulation due to a defect in PDGF signal transduction. CONCLUSION: There is an unmet clinical need to address RA-associated bone loss. Genetic deletion of CD248 in the mouse results in high bone mass due to increased osteoblast-mediated bone formation, suggesting that targeting CD248 in rheumatoid arthritis may have the effect of increasing bone mass as well as the previously reported effect of reducing inflammation.

Statistics

Citations

Dimensions.ai Metrics
15 citations in Web of Science®
15 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 12 Jul 2012
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:12 Jul 2012 06:07
Last Modified:16 Feb 2018 23:37
Publisher:Wiley-Blackwell
ISSN:0004-3591
OA Status:Closed
Publisher DOI:https://doi.org/10.1002/art.34556
PubMed ID:22674221

Download